TODD ANTIN: Open Payments
NPI 1598714073 · DECATUR, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$164,815 in 217 payments from 15 companies in 2025. Trend: 2023 $113,967 · 2024 $165,493 · 2025 $164,815
Speaker / faculty: $136,906Travel & lodging: $11,798Consulting: $11,798Food & beverage: $4,314
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 72 | $93,872 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 74 | $48,670 |
| Vanda Pharmaceuticals Inc. | 27 | $14,427 |
| E.R. Squibb & Sons, L.L.C. | 12 | $7,112 |
| Otsuka America Pharmaceutical, Inc. | 7 | $156 |
| Janssen Pharmaceuticals, Inc | 5 | $128 |
| Neurocrine BioSciences, Inc. | 4 | $121 |
| Axsome Therapeutics, Inc. | 4 | $79 |
| ACADIA Pharmaceuticals Inc | 3 | $64 |
| Collegium Pharmaceutical, Inc. | 3 | $61 |
Products named: AUSTEDO XR, CAPLYTA, UZEDY, FANAPT, COBENFY, REXULTI, INGREZZA, SPRAVATO.
Industry payments across GA — which companies pay providers there.
